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Gabapentin is a well-established anticonvulsant drug which is also effective for the treatment of neuropathic pain. Although
the exact mechanism leading to relief of allodynia and hyperalgesia caused by neuropathy is not known, the blocking effect of
gabapentin on voltage-dependent calcium channels has been proposed to be involved. In order to further evaluate its analgesic
mechanisms, we tested the efficacy of gabapentin on protein kinase C epsilon (PKC𝜀) translocation in cultured peripheral neurons
isolated from rat dorsal root ganglia (DRGs). We found that gabapentin significantly reduced PKC𝜀 translocation induced by the
pronociceptive peptides bradykinin and prokineticin 2, involved in both inflammatory and chronic pain. We recently showed that
paracetamol (acetaminophen), a very commonly used analgesic drug, also produces inhibition of PKC𝜀. We tested the effect of the
combined use of paracetamol and gabapentin, andwe found that the inhibition of translocation adds up. Our study provides a novel
mechanism of action for gabapentin in sensory neurons and suggests a mechanism of action for the combined use of paracetamol
and gabapentin, which has recently been shown to be effective, with a cumulative behavior, in the control of postoperative pain in
human patients.
1. Introduction
Gabapentin, a structural analogue of the inhibitory neuro-
transmitter gamma-aminobutyric acid, was originally devel-
oped in the early nineties as a third-generation antiepileptic
drug. Besides epilepsy, gabapentin has been reported to be
effective for the treatment of other pathological states such
psychiatric and movement disorders, alcohol addiction, and
restless leg syndrome [1]. In particular, gabapentin has been
shown to have central and peripheral antinociceptive activity
in several painful states with neuropathic-related features [2],
including the inflammatory hyperalgesia and allodyniawhich
develop after surgical procedures and may induce central
sensitization and eventually neuropathic pain [3].
Paracetamol is a nonprescription analgesic/antipyretic
drug with little anti-inflammatory activity and partial inhi-
bition of COX-1 and COX-2 [4, 5], of widespread use
both as a self-administered medication and in the clinical
practice. The combination of gabapentin and paracetamol
has been successfully used in postoperative patients, showing
additive effect onmorphine sparing [6]. Little is known about
how gabapentin and paracetamol combine their actions
to produce analgesia, but the additive effect suggests that
convergence on related mechanisms may be hypothesized.
The epsilon isoform of protein kinase C (PKC𝜀) is a
very important noxious effector [7, 8] currently regarded
as a novel target for therapeutic intervention. PKC𝜀 is
involved in both inflammatory and neuropathic pain states
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[9–12] caused by diabetes [13] and alcohol abuse [14] and
during chemotherapy [15]. Translocation is necessary to allow
phosporylation by PKC𝜀 of specific cellular targets located in
the plasmamembrane in nociceptive neurons [16, 17], includ-
ing TRPV1 (Transient Receptor Potential Vanilloid 1) ion
channels [18] and several other targets involved in nociceptor
sensitization and excitability. Inhibition of translocation in
peripheral fibers will prevent phosphorylation activity and
result in antinociceptive effects in sensory neurons. Indeed,
local, intradermal injection of PKC𝜀 specific inhibitors at
the site of nociceptive testing significantly inhibited pain in
severalmodels of peripheral hyperalgesia [13–15].We recently
showed that nimesulide, a nonsteroidal anti-inflammatory
drug (NSAID), and paracetamol inhibit translocation of
PKC𝜀 induced in cultured sensory neurons by bradykinin
and thrombin, inflammatory mediators that sensitize TRPV1
to heat stimuli and to capsaicin [18–21]. We therefore
proposed that nimesulide and paracetamol may exert a
significant part of their analgesic effects with a mechanism
of action based on PKC𝜀 inhibition of translocation in DRG
neurons.
In this paper, to elicit translocation, as well as bradykinin
[12, 22], we use the peptide prokineticin 2 (PK2), involved
in both inflammatory [23–25] and neuropathic [25] states,
which activate PKC𝜀 via Gq-coupled receptors in nociceptive
neurons [16, 23]. We show with a well-established immuno-
cytochemistry technique that gabapentin significantly and
dose-dependently inhibits PKC𝜀 translocation induced by
bradykinin and PK2, with an effect that adds up to the effect
of paracetamol.
2. Materials and Methods
2.1. Dorsal Root Ganglion Primary Cultures. Sprague-Dawley
rats (2–6 weeks old) were sacrificed under total anaesthesia
according to Italian and European legislation, with protocols
in agreement with the guidelines of the Committee for
Research and Ethical Issues of IASP published in PAIN,
16 (1983) pp. 109-110. Experimental protocols were also
approved by local institutional animal care and use commit-
tee. Dorsal root ganglia (DRGs) were collected, incubated
for 1 h at 37∘C with 0.125% collagenase (Sigma-Aldrich,
Milan, IT), mechanically dissociated, and then plated onto
glass coverslips precoated with 10 𝜇g/mL poly-L-lysine and
10 𝜇g/mL laminin (Sigma). Cells were cultured in DMEM
in the presence of 1.5𝜇g/mL cytosine 1-D-arabinofuranoside
(ARA-C, from Sigma), 10% fetal bovine serum, 1% peni-
cillin/streptomycin, and 1% L-glutamine (Invitrogen, San
Diego, CA), and 100 ng/mL NGF (7s, Sigma) was also added
as described previously, in order to improve neuronal survival
and bradykinin and PK2 receptor expression, as it is common
practice with this preparation [23, 26, 27].
2.2. Immunocytochemistry. Translocation of PKC𝜀 from the
cytoplasm to the plasma membrane was visualized as pre-
viously described [12, 19, 23]. In brief, rat DRG neurons
cultured for 2 days were rapidly exposed to bradykinin
at 1 𝜇M concentration or to PK2 (100 nM) for 30 s and
fixed for 10min at room temperature with paraformaldehyde
(4% formaldehyde and 4% sucrose, in PBS/distilled water
2 : 1). Cells were pretreated for different times and differ-
ent concentrations of gabapentin (see Results) alone or in
combination with paracetamol at different concentrations
(see Results). Water was used to prepare stock solutions for
gabapentin, while DMSO was used for paracetamol. Final
concentration of DMSO applied to cells was 1 : 1000, equal
in all experiments. The stimulation with PK2 or bradykinin
contained the same concentrations of drugs preapplied. Fixed
cells were washed three times in PBS (with 0.1% fish skin
gelatin to block nonspecific sites), permeabilized for 30min
at room temperature with Triton X-100 (0.2% in PBS with no
divalent ions added), and incubated overnight at 4∘C with a
polyclonal anti-PKC𝜀 antibody [16] diluted 1 : 1000 in PBS-
T/gelatin (PBS with 0.05% Triton X-100). Coverslips were
rinsed several times with PBS and then stained overnight
with donkey anti-rabbit IgG conjugated to the fluorophore
Alexa Fluor 488 (1 : 1000, Thermo Scientific, Waltham, MA,
USA). Finally, the secondary antibody was rinsed off with
PBS and cells were analyzed using a confocal microscope
(Leica SP2, Leica Microsystems, Milan, Italy). Activation
of PKC𝜀 following activation of bradykinin or prokineticin
receptors (PKRs) resulted in translocation from the cyto-
plasm to the neuronal cell membrane, as shown several times
before [19, 20]. Translocation was quantified by determining
fluorescence intensity along a line positioned across the cell
in order to avoid the nucleus (for details, see Cesare et
al. [21]) using semiautomated proprietary software which
significantly improved efficiency of data analysis. Neurons
in which intensity at the cell membrane was at least 2.0x
greater than the mean of cytoplasmic intensity were counted
as positive. In order to improve data reproducibility and
signal/noise ratio, a very large number of cells were counted:
>1000 cells per coverslip, at least 3-4 coverslips per culture,
3–12 cultures per data point. All experiments were analyzed
in blind conditions.
2.3. Statistical Analysis. Data were analyzed by one-way
analysis of variance (ANOVA), followed by Bonferroni’s 𝑡-
test for multiple comparison. An effect was determined to be
significant if the 𝑃 value was below 0.05.
3. Results
PKC𝜀 activation was quantified in an all-or-nothing fashion
as the number of neurons in which translocation is observed
(see Figure 1), in a very large number of neurons per
each experiment, in order to enhance the resolution of this
technique (see Methods). Using this experimental approach,
it is possible to quantitate the effect of drugs interfering with
translocation and to obtain dose-response and time-course
curves [23]. Following application of 1 𝜇M bradykinin or
100 nM prokineticin 2, which are saturating concentrations
for these agonists, maximum translocation was consistently
observed. Longer application times were avoided as they
would cause PKC𝜀 to be internalized, as shown and discussed
previously [16, 19, 20, 23, 28]. In this set of experiments,
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Figure 1: Confocal optical sections of cultured sensory neurons
treated with prokineticin 2 (100 nM) for 30 seconds and sub-
sequently fixed and stained for PKC𝜀 with a polyclonal specific
antibody. Nuclei were stained in blue with DAPI.The largest neuron
is showing translocation of PKC𝜀 to the plasma membrane; the
smaller neurons represent a typical example of nontranslocated
neurons. Translocation induced by 1𝜇M bradykinin (BK) for 30
seconds had identical appearance. Scale bar: 5𝜇m.
bradykinin at 30 s produced translocation in 32.0 ± 0.6%
and PK2 in 23.6 ± 0.5% of DRG neurons, consistently with
previous work [12, 16, 19, 20, 26].
As shown in Figure 2(a), the percentage of neurons in
which bradykinin receptor activation caused translocation
was dose-dependently decreased by 5min preapplication
of gabapentin in the range 10 nM–500𝜇M to a value of
26.8 ± 0.7% for the largest concentration tested. Inhibition
therefore was about 17.8%. Similarly, the control value of
translocation for PK2 experiments decreased to 17.6 ± 0.5
for the concentration of 200𝜇M gabapentin, with overall
inhibition of about 34%.
Dose-response curves were well fitted with the Hill equa-
tion with the following parameters: for bradykinin-induced
translocation, gabapentin ED
50
= 3.8 ± 0.7 𝜇M and Hill slope
= 0.5±0.1; for PK2-induced translocation, ED
50
= 1.9±0.3 𝜇M
and Hill slope = 0.7 ± 0.1.
Dose responses were obtained after 5min pretreatment
with gabapentin, applied in culture medium and present also
in the bradykinin or PK2 stimulation solution. In Figure 2(b),
we show that longer treatments (30min, 2 hours, and 24
hours) produced no significant time-dependent change in the
fractional effect of gabapentin at 200𝜇M concentration.
As described in Figure 3(a), paracetamol (10 𝜇M), as
previously observed [19, 20], inhibited translocation by
bradykinin. In this new set of experiments, translocation was
reduced from the control value of 32.3 ± 0.9 to 21.5 ± 0.4%. A
similar result was obtained with PK2-induced translocation
from 23.6±0.2% to 19.0±0.5%.All experiments were repeated
in 5 different cultures.
Combined application of gabapentin and paracetamol
resulted in summation of the respective effects, with a
reduction from the control value to 16.2 ± 0.3% and to 13.2 ±
0.4%, respectively, in experiments with bradykinin and with
PK2.
In order to further investigate the nature of the apparently
additive behavior of gabapentin and paracetamol effect, we
performed a full isobolographic analysis, which confirmed
an additive behavior, with no sign of synergistic interaction
(Figure 3(b)).
4. Discussion
Gabapentin, paracetamol, nonsteroid anti-inflammatory
drugs (NSAIDs), selective COX-2 inhibitors, and glucocor-
ticoids are nonopioid drugs which display clinically relevant
analgesic properties. In postoperative pain management,
patients are very often treated with combinations of the above
nonopioid analgesics to reduce opioid-related adverse effects.
Although a variety of combinations have recently been tested
and although some of them are currently employed in clinical
practice [29], the rationale and the molecular mechanisms
behind the combined use of nonopioid analgesic drugs are
often not quite well documented. Recently, it was shown
that gabapentin in combination with other drugs with
minimal adverse effects such as paracetamol [30] allowed
significant opioid sparing with positive effects in postsurgical
patients. So far, gabapentin was believed to produce its
antinociceptive effects mainly by actions on voltage-gated
ion channels, neurotransmitter ionotropic receptors, and
L-amino acid transporters [31]. Such actions are therefore
supposed to occur centrally, where most of such sites of
action are located. Indeed, gabapentin actions both in spinal
and in supraspinal sites have been described [32]. Previously,
some involvement of PKC in antinociceptive effects of
gabapentin was reported in the trigeminal nucleus [33]
and in spinal cord dorsal horn [34]. In a very recent report
[35], this result was confirmed, with indirect evidence of
the involvement of dorsal horn 𝜀 and 𝛾 PKC isoforms in
a visceral pain model [36]. The western blot technique
employed in those studies does not allow discrimination of
the cell localization where PKC𝜀 inhibition of translocation
occurs, but a contribution of presynaptic PKC𝜀, present in
the central terminal of the sensory neuron, consistent with
the one we report here, is largely possible. The 𝛾 isoform of
PKC (PKC𝛾) is not expressed in dorsal root ganglia [16];
therefore, activation of PKC𝛾 can only occur downstream of
the sensory neuron, or in surrounding nonneuronal cells. In
this context, our paper contributes the first demonstration of
PKC-involving antinociceptive functions of gabapentin in
the therapeutic range of concentrations in the peripheral
nervous system, by providing the first direct evidence that a
dose-dependent, significant effect is produced by gabapentin
with a mechanism that involves specific inhibition of
translocation of the 𝜀 PKC isoform in sensory neurons. This
mechanism is likely a relevant part of gabapentin antinoci-
ceptive action, as the lack of translocation will prevent
sensitization of membrane targets in the significant percent-
age of sensory neurons where complete inhibition occurs.
The present study shows also that the effect of gabapentin
combined with paracetamol, in comparison to each drug
alone, adds to the effect of each other. This observation
is consistent with a previous study on acute postoperative
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Figure 2: PKC translocation induced by bradykinin and PK2 is dose-dependently inhibited by gabapentin. (a) Gabapentin dose-response
data on bradykinin-induced (white square symbols) and PK2-induced translocation (white circles). Gabapentin was preapplied for 5minutes,
and then neurons were treated with 1𝜇M bradykinin or 100 nM PK2 for 30 s in the presence of the same preapplied concentration. (b) Time
course of translocation at different times in control culture medium (black symbols) and in the samemediumwith 200𝜇Mgabapentin added
(white symbols). Both bradykinin- and PK2-induced translocation and gabapentin effect are not time-dependent in these conditions. See
Results for further details. Notes: values are means ± SEM of data from 4–7 separate cultures.
pain, demonstrating that the combination of gabapentin and
paracetamol reduced morphine self-administration in a ran-
domized and double-blinded manner in human patients suf-
fering frompostoperative pain [6]. Although in that study it is
not possible to discriminate between peripheral and central
effects of these drugs, our study suggests that the peripheral
effect is likely to contribute significantly to the overall
analgesia. In this context, the observed inhibition of PKC𝜀
translocation by gabapentin and by paracetamol appears to be
highly relevant for a proper understanding of the multifacto-
rial pharmacological actions of these drugs. Inhibitory effects
by gabapentin and paracetamol were largely similar both in
bradykinin- and in PK2-induced translocation, suggesting
that these drugs do not specifically interact with bradykinin
andPK2membrane receptors but rather affectmechanisms of
translocation intracellular pathway, possibly directly onPKC𝜀
itself, or on the interaction of PKC𝜀with the receptors for the
specific activated protein kinase C isoform, RACKs [37]. The
fact that gabapentin and paracetamol effects on PKC𝜀 are
additive suggests that the overall inhibition of translocation
is likely obtained with one or perhaps two differentmolecular
mechanisms activated by each drug, converging on the same
downstream action on PKC𝜀, which are present in specific
subsets of neurons. Sensory neurons are well known to
represent a highly heterogeneous population, with different
morphological, neurochemical, and biochemical properties
[38]. The observation that the gabapentin-induced reduction
of fractional suppression of translocated neurons is about
double for PK2-stimulated in comparison to bradykinin-
stimulated neurons (see Results) is consistent with the
difference in populations expressing the PK2 receptor, the
latter almost exclusively isolectin B4-negative [23] and the
The Scientific World Journal 5
0
5
10
15
20
25 PK2
0
10
20
30
40 BK
∗∗∗
∗∗∗
∗∗∗
∗∗∗ ∗∗∗
∗∗∗
CT
RL
G
ab
ap
en
tin
2
0
0
𝜇
M
Pa
ra
ce
ta
m
ol
1
0
𝜇
M
G
ab
ap
.+
pa
ra
ce
ta
m
ol
CT
RL
G
ab
ap
en
tin
2
0
0
𝜇
M
Pa
ra
ce
ta
m
ol
1
0
𝜇
M
G
ab
ap
.+
pa
ra
ce
ta
m
ol
Tr
an
slo
ca
tio
n 
(%
)
(a)
0 1 2 3
0
1
2
3
4
0.0 0.5 1.0 1.5 2.0
0.0
0.5
1.0
1.5
2.0
BK PK2
[G
ab
ap
en
tin
] (
𝜇
M
)
[G
ab
ap
en
tin
] (
𝜇
M
)ED50 gabapentin
ED50 cotreatment
ED50 paracetamol
ED50 gabapentin
ED50 cotreatment
ED50 paracetamol
[Paracetamol] (𝜇M) [Paracetamol] (𝜇M)
(b)
Figure 3: PKC translocation suppression by gabapentin and by paracetamol is additive. (a) Experiments on bradykinin- (BK-) induced and
PK2-induced PKC𝜀 translocation. Gabapentin effect on the latter was almost double compared to the former, with about 14.2% suppression on
bradykinin-induced translocation and 25.4% suppression on PK2-induced translocation, compared to control (CTRL). Paracetamol-induced
suppression was 33.4% (BK) and 21.6% (PK2). Combined drug suppression was, respectively, 49.8% and 41.9%, consistent with an additive
effect of these drugs. (b) Isobolograms for the effects of gabapentin and paracetamol, alone or in combination, in BK- and PK2-induced
PKC𝜀 translocation. White square symbols correspond to the experimental cotreatment ED
50
with 95% confidence limits. Circle symbols
correspond to ED
50
for gabapentin and paracetamol alone. Notes: values are means ± SEM of data from 5 separate cultures. ∗∗∗𝑃 < 0.001
versus control and versus other treatments in all combinations (ANOVA followed by Bonferroni’s 𝑡-test).
former both isolectin B4-positive and isolectin B4-negative
(unpublished observation, consistent with the literature [12,
39, 40]) only partially overlapping [23].
More work is necessary to determine the nature of mech-
anisms preventing translocation in these specific subsets of
neurons. Further experiments that will determine whether
other novel or classic antinociceptive drugs currently in use,
as well as paracetamol and gabapentin, produce part of
their effect via inhibition of PKC𝜀 translocation and whether
their combined effects are additive or possibly synergistic are
currently in progress in our labs.
5. Conclusion
In conclusion, our results help to clarify the pharmacological
action of largely used drugs such as gabapentin and paraceta-
mol and of their combined use. From these results, in com-
bination with data in the literature, gabapentin emerges as a
drugwithmultifactorialmodes of action on the pain pathway,
with an increasing number of novel, interesting mechanisms
not only in the central but also in the peripheral nervous
system.
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